SCHEDULE: ARCH Venture Funds Divest Entire Unity Biotech Stake

ARCH Venture Funds and their managing directors have reported a complete divestment of their beneficial ownership in Unity Biotechnology, Inc., now holding 0% of common stock.

Summary

• ARCH Venture Fund VII, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, and ARCH Venture Partners VIII, LLC, along with managing directors Keith Crandell, Clinton Bybee, and Robert Nelsen, have reported 0% beneficial ownership in Unity Biotechnology, Inc.
• This filing is Amendment No. 4 to a Schedule 13G, indicating a change from previously reported ownership to a complete divestment.
• The event requiring this filing, where beneficial ownership dropped to 0%, occurred on September 30, 2025.
• The reporting persons collectively hold no sole or shared voting or dispositive power over Unity Biotechnology, Inc. common stock.

Sentiment

Score: 2

Explanation: The complete divestment by a significant venture capital firm is a strong negative signal, indicating a lack of confidence in the company's future prospects and potentially signaling a re-evaluation of its investment thesis.

Negatives

• A significant venture capital investor group, ARCH Venture Funds, has fully divested its stake in Unity Biotechnology, Inc., reducing its beneficial ownership to 0%.
• This complete divestment by a sophisticated institutional investor could signal a lack of confidence in the company's future prospects or strategic direction.

Risks

• The complete divestment by ARCH Venture Funds may be interpreted by the market as a negative signal regarding Unity Biotechnology, Inc.'s long-term viability or potential.
• Reduced institutional ownership could lead to decreased liquidity and increased stock price volatility for Unity Biotechnology, Inc. shares.

Industry Context

The complete divestment by a prominent biotech venture capital firm like ARCH Venture Partners from a biotechnology company like Unity Biotechnology, Inc. could be seen as a significant event within the biotech investment community. Such actions often reflect a re-evaluation of the company's pipeline, market potential, or overall strategy, potentially influencing other investors' perceptions and decisions in the sector.

Stakeholder Impact

• Shareholders: Existing shareholders may experience a negative impact on share price due to the perceived loss of institutional confidence and potential selling pressure from the market reacting to the divestment.
• Potential Investors: New investors may be deterred by the complete exit of a major venture capital firm, leading to reduced demand for the company's stock.

Key Dates

Recommendation

The complete divestment by ARCH Venture Funds, a prominent institutional investor, signals a significant loss of confidence in Unity Biotechnology, Inc.'s future. This action by a sophisticated investor often precedes negative market sentiment and potential share price decline, warranting a 'sell' recommendation for existing holders and caution for potential investors.

Keywords

Unity Biotechnology, ARCH Venture, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, biotech, venture capital